PL EN
Experts and national consultants’ recommendations regarding management of patients treated for migraine with comorbid depression. Diagnosis. Therapeutic strategies. Part 2
 
More details
Hide details
1
Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny MON, Klinika Neurologiczna
 
2
Uniwersytet Jagielloński Collegium Medicum, Katedra i Klinika Neurologii
 
3
Warszawski Uniwersytet Medyczny, Wydział Medyczny, Klinika Neurologii
 
4
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Katedra Klinika Neurologii
 
5
Lubelski Uniwersytet Medyczny, Katedra i Klinika Neurologii
 
6
Uniwersytet Medyczny w Łodzi, Klinika Neurologii, Udarów Mózgu i Neurorehabilitacji
 
7
Szpital Uniwersytecki w Krakowie, Kliniczny Oddział Anestezjologii i Intensywnej Terapii nr 1
 
8
Uniwersytet Jagielloński Collegium Medicum, Klinika Leczenia Bólu i Opieki Paliatywnej
 
9
Uniwersytet Jagielloński Collegium Medicum, Katedra Farmakologii, Zakład Farmakologii Klinicznej
 
10
Uniwersytet Medyczny w Łodzi, Klinika Psychiatrii Dorosłych
 
 
Submission date: 2021-04-09
 
 
Final revision date: 2021-05-31
 
 
Acceptance date: 2021-06-29
 
 
Online publication date: 2022-08-31
 
 
Publication date: 2022-08-31
 
 
Corresponding author
Piotr Gałecki   

Klinika Psychiatrii Dorosłych, Uniwersytet Medyczny w Łodzi
 
 
Psychiatr Pol 2022;56(4):711-728
 
KEYWORDS
TOPICS
ABSTRACT
Depressive disorders are currently diagnosed based on the ICD-10 and DSM-5 diagnostic criteria and include axial depressive symptoms and additional symptoms that must coexist for at least two weeks. Migraine is diagnosed based on the International Classification of Headache Disorders. It is generally divided into migraine with and without aura, and with regard to the frequency of attacks into episodic and chronic migraine. The therapeutic strategy in the treatment of depression is pharmacotherapy combined with psychotherapy, whereas in the treatment of migraine the strategy depends on the frequency of headache attacks (episodic migraine vs. chronic migraine) and comorbidities. A novelty is the introduction of monoclonal antibodies directed against CGRP or the receptor of CGRP. There are numerous reports which indicate specific usefulness of monoclonal antibodies that modify the action of CGRP in the treatment of migraine in people suffering from depression.
eISSN:2391-5854
ISSN:0033-2674
Journals System - logo
Scroll to top